Aktiesnakken — Juli 2010
-
no fill
-
Ja, godaften
-
okay, bare fordi jeg lige snakkede med familien
-
godaften alle, jeg har ikke set en eneste analyse der har prissat ms i arzerra. Jo der var i 2006 en analyse fra lehmann med kursmål 1100
-
ms og ra er meget store indikationer
-
men det er som doctor siger kun fase 2
-
og der er lang vej endnu, GSK må have vidst resultaterne
-
netop doctor
-
men hvis Arzerra også have en fremtid i autoimmune så er værdien er arzerra nok lige fordoblet til 170 kr. per aktie
-
gsk har kendt resultaterne
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind